Divisun 2000 IU tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

divisun 2000 iu tabletti

viatris oy - cholecalciferol concentrate (powder form) - tabletti - 2000 iu - kolekalsiferoli (vitamiini d3)

Duphagol 13.8 g jauhe oraaliliuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

duphagol 13.8 g jauhe oraaliliuosta varten

viatris oy - potassium chloride, sodium hydrogen carbonate, macrogol 3350, sodium chloride - jauhe oraaliliuosta varten - 13.8 g - makrogoli

Duphagol Junior 6.9 g jauhe oraaliliuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

duphagol junior 6.9 g jauhe oraaliliuosta varten

viatris oy - potassium chloride, sodium hydrogen carbonate, macrogol 3350, sodium chloride - jauhe oraaliliuosta varten - 6.9 g - makrogoli

Zyx Eukalyptus 3 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

zyx eukalyptus 3 mg imeskelytabletti

viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini

Creon 20 000 enterokapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

creon 20 000 enterokapseli, kova

viatris oy - pancreas powder - enterokapseli, kova - useita entsyymejä (lipaasi

Creon 35 000 enterokapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

creon 35 000 enterokapseli, kova

viatris oy - pancreas powder - enterokapseli, kova - useita entsyymejä (lipaasi

Femke 30 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

femke 30 mg tabletti, kalvopäällysteinen

viatris limited - ulipristal acetate - tabletti, kalvopäällysteinen - 30 mg - ulipristaali

Influvac Tetra 15/15/15/15 µg/annos injektioneste, suspensio, esitäytetty ruisku Suomi - suomi - Fimea (Suomen lääkevirasto)

influvac tetra 15/15/15/15 µg/annos injektioneste, suspensio, esitäytetty ruisku

viatris oy - influenza a virus h3n2, live, attenuated, influenza b virus, live, attenuated, influenza a virus h1n1, live, attenuated, influenza b virus, live, attenuated, victoria lineage - injektioneste, suspensio, esitäytetty ruisku - 15/15/15/15 µg/annos - influenssarokote

Zyx Appelsiini & Hunaja 3 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

zyx appelsiini & hunaja 3 mg imeskelytabletti

viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Euroopan unioni - suomi - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.